🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

30 results for “ivonescimab” Clear

  1. Drug: Ivonescimab Injection

    Summit Therapeutics

    Metastatic Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  2. FLUOROURACIL, BEVACIZUMAB, FOLINIC ACID, OXALIPLATIN, ivonescimab

    Summit Therapeutics

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  3. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)

    phase 3 small molecule active

    1 trial

  4. Ivonescimab Injection

    Summit Therapeutics

    Non-Small Cell Lung Cancer

    phase 3 mab active

    2 trials

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ivonescimab, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin 10 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion., Pazenir 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion

    Summit Therapeutics

    Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Summit Therapeutics

    Metastatic Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. CALCIUM FOLINATE, ivonescimab, CALCIUM LEVOFOLINATE, OXALIPLATIN, FLUOROURACIL

    Ningbo Cancer Hospital

    Advanced biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  8. GnP in combination with Ivonescimab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  9. IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL

    Ningbo Cancer Hospital

    Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)

    phase 2 small molecule active

    1 trial

  10. Ivonescimab

    Summit Therapeutics

    Glioblastoma

    phase 2 small molecule active

    1 trial

  11. Ivonescimab

    Summit Therapeutics

    Ivonescimab

    phase 2 small molecule active

    1 trial

  12. Ivonescimab

    Summit Therapeutics

    Advanced Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  13. Ivonescimab

    Summit Therapeutics

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  14. Ivonescimab

    Summit Therapeutics

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  15. Ivonescimab

    Summit Therapeutics

    Endometrial Cancer

    phase 2 small molecule active

    1 trial

  16. Ivonescimab

    Summit Therapeutics

    Pleural Mesotheliomas

    phase 2 small molecule active

    1 trial

  17. Ivonescimab

    Summit Therapeutics

    Salivary Gland Cancer

    phase 2 small molecule active

    1 trial

  18. Ivonescimab

    Summit Therapeutics

    Stomach Cancer Stage IV

    phase 2 small molecule active

    1 trial

  19. Ivonescimab

    Summit Therapeutics

    Thymus Carcinoma

    phase 2 mab active

    1 trial

  20. Ivonescimab

    Summit Therapeutics

    TNBC

    phase 2 small molecule active

    1 trial

  21. Ivonescimab

    Summit Therapeutics

    Leiomyosarcoma

    phase 2 small molecule active

    1 trial

  22. Ivonescimab

    Summit Therapeutics

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  23. Ivonescimab

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  24. Ivonescimab

    Summit Therapeutics

    Metastatic Esophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources